Filing identity and reporting period
Important mismatch: The request identifies Newegg Commerce, Inc. and 2013 Q4, but the supplied filing is Dehaier Medical Systems Limited’s audited Form 20-F for the fiscal year ended December 31, 2013. It does not provide separate fourth-quarter results. The summary below reflects the supplied filing, not Newegg.
Dehaier develops and distributes medical equipment and sleep-respiratory and oxygen-therapy products, principally in China. Its financial statements are prepared under U.S. GAAP and reported in U.S. dollars.
Financial performance and position
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Revenue | $16.86 million | $21.37 million |
| Gross profit / margin | $6.41 million / 38.03% | $8.12 million / 37.98% |
| Operating income | $3.51 million | $4.39 million |
| Net income | $2.00 million | $3.22 million |
| Net income attributable to Dehaier | $2.00 million | $3.21 million |
| Basic and diluted EPS | $0.43 | $0.70 |
| Operating cash flow | $(0.20) million | $1.70 million |
| Cash and cash equivalents at year-end | $2.59 million | $3.51 million |
| Working capital at year-end | $32.62 million | $28.85 million |
| Short-term borrowings at year-end | $2.48 million | $2.41 million |
FY 2013 investing cash outflow was $1.13 million, mainly for equipment purchases. Financing provided $0.33 million net: $2.50 million of loan proceeds was nearly offset by $2.50 million of repayments. Year-end total assets were $42.21 million, total liabilities $4.53 million, and total equity $37.68 million.
Changes versus the prior year
- Revenue fell 21.11%, which management attributed to tougher competition, new market entrants, and a strategic shift of resources toward sleep-respiratory products and away from traditional device sales.
- Gross profit declined, but gross margin edged up from 37.98% to 38.03%, which management attributed to product-mix changes and emphasis on higher-margin sales.
- Operating income declined 20.11%; net income declined 37.72%. The 2013 result also included a $473,709 loss on disposal of equipment and a $346,691 warrant-liability fair-value expense.
- Operating cash flow swung from positive $1.70 million to negative $0.20 million. Management cited increased prepayments and other current assets, including supplier prepayments intended to secure costs, as a key factor.
- Research and development expense increased to $484,770 from $230,854. The company reported 104 employees at year-end, down from 165 in 2012.
Outlook, risks, and notable items
Management said sleep-respiratory and oxygen-therapy revenue could grow faster than total revenue in the near term, but described the business as early-stage. Its stated 2014 priorities were to establish a stronger foundation through product introductions and market development; it did not provide numerical guidance. Management also cited potential opportunities from China’s healthcare investment and government policies, while acknowledging margin pressure in traditional devices.
- Key risks include competition and pricing pressure, reliance on distributors and a concentrated product mix, regulatory approvals and renewals, product liability exposure with limited insurance, and reliance on third-party suppliers and manufacturers.
- Customer concentration warrants attention: the filing reports approximately 26% of 2013 revenue associated with two major customers, but its wording does not clearly establish whether that percentage applies to each customer or to both together. The top three products represented approximately 67% of revenue.
- Cash conversion and working-capital quality are important: year-end advances to suppliers were $7.08 million and prepayments and other current assets were $5.60 million. Receivables were $12.62 million net of allowance.
- Year-end borrowings were secured by BTL’s building and guaranteed by BDL and a company officer. The filing says the existing loans were repaid in January 2014 and a new $2.48 million loan was entered into, due January 2015. The filing also reports approximately $6.7 million gross proceeds from a February 2014 share-and-warrant offering, or about $6.07 million net.
- Other notable matters include a 15% PRC tax rate based on high-technology certification, foreign-exchange and dividend-repatriation restrictions, and a disclosed estimate of $336,341 in possible employee severance payments not recorded as a liability.
The auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not audit or opine on internal control.
Investor verification checklist
- Confirm the issuer and period: this source is Dehaier’s FY 2013 Form 20-F, not a Newegg filing or a standalone Q4 report.
- Review audited statements and notes for the causes of weaker earnings and negative operating cash flow, particularly supplier prepayments, asset-disposal loss, and warrant remeasurement.
- Clarify the customer-concentration disclosure and assess collectability of receivables and recoverability of supplier advances and prepayments.
- Verify the January 2014 borrowing repayment and replacement loan terms, collateral and guarantee, and the February 2014 offering’s net proceeds and potential dilution.
- Check product registration status, tax certification, and the company’s ability to convert and remit funds from China.